Allan Hildesheim

National Institutes of Health, National Cancer Institute

Papers

Total Citations

H-Index

About

Allan Hildesheim is a leading epidemiologist whose research has fundamentally advanced our understanding of the role of human papillomavirus (HPV) in cervical carcinogenesis. His key contributions lie in the development and validation of HPV genotyping methods, the design of large-scale natural history studies, and the evaluation of preventive interventions. Notably, his work on comparing PCR-based HPV genotyping methods (cited over 80 times) provided critical insights into the accuracy and reliability of techniques used to detect individual and carcinogenic HPV genotypes, directly informing global screening practices. Hildesheim was instrumental in the landmark NCI/Costa Rica HPV16/18 Vaccine Trial, which demonstrated the efficacy of the bivalent HPV vaccine and shaped worldwide immunization policies. His meticulous investigations into the stability of archived cytologic specimens (cited 9 times) also highlighted important methodological considerations for biobanking and retrospective molecular analyses. With a career spanning decades at the National Cancer Institute, Hildesheim has authored hundreds of publications, amassing tens of thousands of citations. His rigorous, translational approach has bridged laboratory science and population-based research, making him a pivotal figure in the fight against HPV-related cancers and a mentor to a generation of cancer epidemiologists.